logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Ovarian cancer: maintenance olaparib extends OS more than 1 year, setting new standard

Final OS results of SOLO2 trial report on maintenance olaparib for platinum-sensitive relapsed ovarian cancer with BRCA mutation.